Skip to main content

Advertisement

Table 2 Characteristics of colloid solutions

From: Pros and cons of tetrastarch solution for critically ill patients

Product Concentration (%) Oncotic pressure (mmHg) Initial volume expansiona(%) Persistence in the body (days) Maximal dose/24 h Carrier solution Effect on hemostasis Comments
Albumin 4 20–29 80 n/a   Na 148 mEq/l 0  
20 100–120 200 ~ 400 Cl 128 mEq/l
Na n/a
Cl 19 mEq/l
Dextran 70 6 56–68 120 28 ~ 42 1.5 g/kg   +++  
Dextran 40 10 168–191 200 6 1.5 g/kg   +++  
Fluid gelatin 4 42 70 2 ~ 7   Na 154 mEq/l 0 ~ +  
90 7
Cl 120 mEq/l
Urea-linked gelatin 3.5 25–29 70 ~ 80 2 ~ 7   Na 145 mEq/l 0 ~ +  
Cl 145 mEq/l
HES 670/0.75 6 25–30 100   20 ml/kg Lactate Ringer ++(+)  
HES 200/0.5 6 30–37 100 3 ~ 4 33 ml/kg   +  
HES 70/0.5 6   80 ~ 90   20 ml/kg Either saline or balanced solution 0 ~ +  
HES 200/0.5 10 59–82 145 3 ~ 4 20 ml/kg   + Used in VICEP study [12]
HES 130/0.4 6 36 100 <1 50 ml/kg Either saline or similar to acetate Ringer but no Ca 0 ~ + Used in CHEST study [13] and CRYSTMAS study [14]
HES 130/0.42 6     33 ml/kg Acetate Ringer   Used in 6S trial [15]
  1. Modified from references [911]. HES products are summarized as in vitro molecular weight/degree of substitution. aExpressed as plasma volume increase/administered volume (%). The number of plus sign suggests the semi-qualitative comparison between each item.